Physician profile
Ivan Rivera
NPI 1720214190
$4,011.46
in general payments reported to CMS, 2019-2025
24 companies · $1,275 in 2025
The $1,275 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.00 · 2020: $12.83 · 2021: $311 · 2022: $415 · 2023: $718 · 2024: $1,210 · 2025: $1,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,202.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,124.01 | 2022-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $800.12 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $489.82 | 2022-2025 | |
| Novo Nordisk INC | $426.04 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Mannkind Corporation | $249.50 | 2021 | |
| Abbott Laboratories | $212.31 | 2022-2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $88.16 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $82.51 | 2024 | Korlym |
| Genzyme Corporation | $70.00 | 2019 | |
| Axsome Therapeutics, INC. | $56.60 | 2025 | Auvelity |
| Amgen INC. | $50.83 | 2022-2025 | Evenity |
| Sanofi-Aventis U.S. LLC | $50.00 | 2021 | |
| Sumitomo Pharma America, INC. | $46.32 | 2023-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $42.99 | 2021-2024 | Farxiga |
| Cipher Pharmaceuticals US LLC | $36.71 | 2025 | Natroba, Spinosad |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $35.64 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $27.83 | 2023 | Rexulti |
| Lifescan, INC. | $22.20 | 2022 | |
| Dynavax Technologies Corporation | $20.38 | 2024 | Heplisav-B |
| Glaxosmithkline, LLC. | $18.47 | 2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.12 | 2025 | Xifaxan |
| Boston Scientific Corporation | $16.10 | 2023 | Watchman Access System |
| Lilly USA, LLC | $14.21 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.